Abstract: Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and/or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.
Type:
Grant
Filed:
February 10, 2005
Date of Patent:
August 16, 2011
Assignees:
National Jewish Medical and Research Center, MUSC Foundation for Research Development, The Regents of the University of Coloraodo
Inventors:
Vernon Michael Holers, Joshua M. Thurman, Christian Taube, Erwin W. Gelfand, Gary Steven Gilkeson